SOX10 distinguishes oligodendrogliomas from low‐grade glioneuronal tumors/low‐grade gliomas with oligodendrocyte‐like features
The Journal of Pathology: Clinical Research · 2026-07 · 12 (4)
DOI: 10.1002/2056-4538.70103 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 01.07.2026. Verfasst von Danmei Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Huashan Hospital, Fudan University, Shanghai, PR China. Hauptthemen laut MEDLINE: SOXE Transcription Factors, Oligodendroglioma, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality, Shanghai Hospital Development Center Foundation, Shanghai Action Plan for Science Technology and Innovation.
Abstract (Originalsprache)
Oligodendrogliomas exhibit significant morphological overlap with low‐grade glioneuronal tumors/low‐grade gliomas with oligodendrocyte‐like features, posing challenges in histopathological diagnosis. SOX10, a transcription factor critical for oligodendrocyte maturation and central nervous system myelination, may serve as a diagnostic marker. We evaluated the diagnostic utility of SOX10 immunohistochemical expression in 300 oligodendrogliomas versus 52 low‐grade glioneuronal tumors/low‐grade gliomas with oligodendrocyte‐like features. Notably, SOX10 was negative in 251/300 (83.7%) oligodendrogliomas but diffusely positive in 47/52 (90.4%) low‐grade glioneuronal tumors/low‐grade gliomas with oligodendrocyte‐like features (except polymorphous low‐grade neuroepithelial tumors of the young, PLNTY). SOX10 expression was significantly higher in the latter group ( p < 0.001) and showed a WHO grade dependent up‐regulation in oligodendrogliomas ( p < 0.001). The diagnostic utility of SOX10 was evident in IDH1‐immunonegative cases, yielding 72% sensitivity, 90.4% specificity, and a 78.3% positive predictive value for oligodendroglioma. Combining H3K27me3 loss with SOX10 negativity markedly improved diagnostic sensitivity for oligodendroglioma to 88.5%, substantially surpassing the 35% sensitivity achieved with H3K27me3 loss alone. Additionally, an immunohistochemical panel comprising SOX10, Olig2, and IDH1 aided in discriminating non‐neoplastic oligodendrocyte hyperplasia from oligodendroglioma and evaluating the presence of peritumoral tumor residue, particularly in IDH1‐immunonegative oligodendroglioma. In conclusion, SOX10 negativity effectively excludes low‐grade glioneuronal tumors/low‐grade gliomas with oligodendrocyte‐like features (except PLNTY) and non‐neoplastic oligodendrocyte hyperplasia from oligodendrogliomas. SOX10 serves as a specific diagnostic marker, enhancing pathological diagnostic accuracy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Huashan Hospital, Fudan University, Shanghai, PR China.
- Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, PR China.
- Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, PR China.
Förderung
- Natural Science Foundation of Shanghai Municipality
- Shanghai Hospital Development Center Foundation
- Shanghai Action Plan for Science Technology and Innovation
- National Natural Science Foundation of China
- National Key Clinical Specialty Construction Project, Beijing, PR China
Zitieren
APA
Zhou, D., Hu, X., Wang, Y., Tang, F., Du, Z., & Xiong, J. (2026). SOX10 distinguishes oligodendrogliomas from low‐grade glioneuronal tumors/low‐grade gliomas with oligodendrocyte‐like features. The Journal of Pathology: Clinical Research, 12(4). https://doi.org/10.1002/2056-4538.70103
Vancouver
Zhou D, Hu X, Wang Y, Tang F, Du Z, Xiong J. SOX10 distinguishes oligodendrogliomas from low‐grade glioneuronal tumors/low‐grade gliomas with oligodendrocyte‐like features. The Journal of Pathology: Clinical Research. 2026;12(4). doi:10.1002/2056-4538.70103
BibTeX
@article{Zhou2026,
author = {Zhou, Danmei and Hu, Xiaomu and Wang, Yin and Tang, Feng and Du, Zunguo and Xiong, Ji},
title = {SOX10 distinguishes oligodendrogliomas from low‐grade glioneuronal tumors/low‐grade gliomas with oligodendrocyte‐like features},
journal = {The Journal of Pathology: Clinical Research},
year = {2026},
volume = {12},
number = {4},
doi = {10.1002/2056-4538.70103}
}
EUVIMED